Compare Oatly Group AB - ADR (OTLY) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Oatly Group AB - ADR trades at $10.52 (market cap $330.93M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.69 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 177.5× Oatly Group AB - ADR's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| OTLY | TAK | |
|---|---|---|
Market Cap | $330.93M | $58.74B |
Volume | 68,708 | 3,110,994 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $19.05 |
52-Week Low | $8.03 | $13.23 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $835.34M | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.37, down 1.33% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. Fundamentally, the company shows improving revenue growth ($862M in 2025, projected $925M in 2026) and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The outlook suggests cautious optimism as Oatly demonstrates operational improvements and revenue acceleration, but significant risks remain including persistent negative cash flow, high debt levels, and competitive pressures in the plant-based beverage market. The stock offers potential for recovery if the company can achieve its projected path toward profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
